CrossGen Wealth LLC Buys New Stake in Merck & Co., Inc. $MRK

CrossGen Wealth LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,290 shares of the company’s stock, valued at approximately $662,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Blue Sparrow LLC DE purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $14,494,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Merck & Co., Inc. by 8.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 775,210 shares of the company’s stock worth $81,599,000 after buying an additional 59,159 shares during the last quarter. Blue Chip Partners LLC boosted its stake in shares of Merck & Co., Inc. by 7.2% in the fourth quarter. Blue Chip Partners LLC now owns 244,829 shares of the company’s stock worth $25,771,000 after buying an additional 16,411 shares during the last quarter. Corecam AG purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $559,000. Finally, Braeburn Wealth Management LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $522,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $114.04 on Friday. The firm has a market cap of $281.65 billion, a PE ratio of 32.12, a P/E/G ratio of 2.60 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The business has a 50-day moving average price of $116.12 and a 200 day moving average price of $113.60.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Analysts Set New Price Targets

A number of research analysts have issued reports on MRK shares. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.